Search Results - "Goeminne, Jean Charles"

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer by BASELGA, José, GOMEZ, Patricia, GOEMINNE, Jean-Charles, GRAAS, Marie-Pascale, KENNEDY, M. John, CIRUELOS GIL, Eva Maria, SCHNEEWEISS, Andreas, ZUBEL, Angela, GROOS, Jutta, MELEZINKOVA, Helena, AWADA, Ahmad, GREIL, Richard, BRAGA, Sofia, CLIMENT, Miguel A, WARDLEY, Andrew M, KAUFMAN, Bella, STEMMER, Salomon M, PEGO, António, CHAN, Arlene

“…Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized…”
Get full text

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer by GIANNI, Luca, LLADO, Anna, HERSBERGER, Veronica, BASELGA, José, BIANCHI, Giulia, CORTES, Javier, KELLOKUMPU-LEHTINEN, Pirkko-Liisa, CAMERON, David A, MILES, David, SALVAGNI, Stefania, WARDLEY, Andrew, GOEMINNE, Jean-Charles

“…Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to…”
Get full text

Phase II study of dual phosphoinositol‐3‐kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma by Seront, Emmanuel, Rottey, Sylvie, Filleul, Bertrand, Glorieux, Philippe, Goeminne, Jean‐Charles, Verschaeve, Vincent, Vandenbulcke, Jean‐Marie, Sautois, Brieuc, Boegner, Petra, Gillain, Aline, Maanen, Aline, Machiels, Jean‐Pascal

“…Objective To assess, in a multicentre phase II trial, the safety and efficacy of BEZ235, an oral pan‐class I phosphoinositol‐3‐kinase (PI3K) and mammalian…”
Get full text

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report by Louvet, Aurélie, Honoré, Natasha, Dekairelle, Anne-France, Van Marcke, Cédric, Goeminne, Jean-Charles

“…A non-small-cell-lung-cancer patient with cerebral metastasis presenting an atypical exon 20 mutation in the EGFR gene had a long-lasting tumor cotrol on…”
Get full text

End-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage by Depoorter, Victoria, Vanschoenbeek, Katrijn, Decoster, Lore, Silversmit, Geert, Debruyne, Philip R, De Groof, Inge, Bron, Dominique, Cornélis, Frank, Luce, Sylvie, Focan, Christian, Verschaeve, Vincent, Debugne, Gwenaëlle, Langenaeken, Christine, Van Den Bulck, Heidi, Goeminne, Jean-Charles, Teurfs, Wesley, Jerusalem, Guy, Schrijvers, Dirk, Petit, Bénédicte, Rasschaert, Marika, Praet, Jean-Philippe, Vandenborre, Katherine, De Schutter, Harlinde, Milisen, Koen, Flamaing, Johan, Kenis, Cindy, Verdoodt, Freija, Wildiers, Hans

“…This study aims to describe end-of-life (EOL) care in older patients with cancer and investigate the association between geriatric assessment (GA) results and…”
Get full text

Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab by Benjamin, Lardinois, Jean-Charles, Goeminne, Laurence, Miller, Adrien, Randazzo, Terry, Laurent, Régis, Debois

“…Immune-related adverse events including cardiac toxicity are increasingly described in patients receiving immune checkpoint inhibitors. We described a…”
Get full text

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program by Van Praet, Charles, M.D, Rottey, Sylvie, M.D., Ph.D, Van Hende, Fransien, M.D, Pelgrims, Gino, M.D, Demey, Wim, M.D, Van Aelst, Filip, M.D, Wynendaele, Wim, M.D, Gil, Thierry, M.D, Schatteman, Peter, M.D, Filleul, Bertrand, M.D, Schallier, Dennis, M.D., Ph.D, Machiels, Jean-Pascal, M.D., Ph.D, Schrijvers, Dirk, M.D, Everaert, Els, M.D, D’Hondt, Lionel, M.D, Werbrouck, Patrick, M.D, Vermeij, Joanna, M.D, Mebis, Jeroen, M.D, Clausse, Marylene, M.D, Rasschaert, Marika, M.D, Van Erps, Joanna, M.D, Verheezen, Jolanda, M.D, Van Haverbeke, Jan, M.D, Goeminne, Jean-Charles, M.D, Lumen, Nicolaas, M.D., Ph.D

“…Abstract Background Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data on oncological…”
Get full text

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial by Vandeputte, Caroline, Bregni, Giacomo, Gkolfakis, Paraskevas, Guiot, Thomas, Pretta, Andrea, Kehagias, Pashalina, Senti, Chiara, Reina, Elena Acedo, Van Bogaert, Camille, Deleporte, Amélie, Geboes, Karen, Delaunoit, Thierry, Demolin, Gauthier, Peeters, Marc, D'Hondt, Lionel, Janssens, Jos, Carrasco, Javier, Holbrechts, Stephane, Goeminne, Jean-Charles, Vergauwe, Philippe, Van Laethem, Jean-Luc, Flamen, Patrick, Hendlisz, Alain, Sclafani, Francesco

“…Regorafenib is a standard treatment for refractory metastatic colorectal cancer (mCRC). In view of the toxicity burden, significant research efforts have been…”
Get full text

Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors by Lodewijckx, Elke, Kenis, Cindy, Flamaing, Johan, Debruyne, Philip, De Groof, Inge, Focan, Christian, Cornélis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Luce, Sylvie, Debugne, Gwenaelle, Van den Bulck, Heidi, Goeminne, Jean-Charles, Schrijvers, Dirk, Geboers, Katrien, Petit, Benedicte, Langenaeken, Christine, Van Rijswijk, Ruud, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, Vandenborre, Katherine, Lobele, Jean-Pierre, Milisen, Koen, Wildiers, Hans, Decoster, Lore

“…Background: This study aims to investigate the occurrence of unplanned hospitalizations in older patients with cancer and to determine predictive factors…”
Get full text

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program by Joris, Sofie, Pieters, Thierry, Sibille, Anne, Bustin, Fréderique, Jacqmin, Laurence, Kalantari, Hassan Rezaei, Surmont, Veerle, Goeminne, Jean-Charles, Clinckart, Frederic, Pat, Karin, Demey, Wim, Deschepper, Koen, Lambrechts, Marc, Holbrechts, Stephane, Schallier, Denis, Decoster, Lore

“…To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group…”
Get full text

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes by Depoorter, Victoria, Vanschoenbeek, Katrijn, Decoster, Lore, De Schutter, Harlinde, Debruyne, Philip R., De Groof, Inge, Bron, Dominique, Cornélis, Frank, Luce, Sylvie, Focan, Christian, Verschaeve, Vincent, Debugne, Gwenaëlle, Langenaeken, Christine, Van Den Bulck, Heidi, Goeminne, Jean-Charles, Teurfs, Wesley, Jerusalem, Guy, Schrijvers, Dirk, Petit, Bénédicte, Rasschaert, Marika, Praet, Jean-Philippe, Vandenborre, Katherine, Milisen, Koen, Flamaing, Johan, Kenis, Cindy, Verdoodt, Freija, Wildiers, Hans

“…Geriatric screening and geriatric assessment (GS/GA) have proven their benefits in the care for older patients with cancer. However, less is known about the…”
Get full text

Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium by Depoorter, Victoria, Vanschoenbeek, Katrijn, Decoster, Lore, Silversmit, Geert, Debruyne, Philip R, De Groof, Inge, Bron, Dominique, Cornélis, Frank, Luce, Sylvie, Focan, Christian, Verschaeve, Vincent, Debugne, Gwenaëlle, Langenaeken, Christine, Van Den Bulck, Heidi, Goeminne, Jean-Charles, Teurfs, Wesley, Jerusalem, Guy, Schrijvers, Dirk, Petit, Bénédicte, Rasschaert, Marika, Praet, Jean-Philippe, Vandenborre, Katherine, Milisen, Koen, Flamaing, Johan, Kenis, Cindy, Verdoodt, Freija, Wildiers, Hans

“…Little evidence is available on the long-term health-care utilisation of older patients with cancer and whether this is associated with geriatric screening…”
Get full text

Health related quality of life in older patients with solid tumors and prognostic factors for decline by Decoster, Lore, Quinten, Chantal, Kenis, Cindy, Flamaing, Johan, Debruyne, Philip R., De Groof, Inge, Focan, Christian, Cornelis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Luce, Sylvie, Debugne, Gwenaëlle, den Bulck, Goeminne, Jean-Charles, Baitar, Abdelbari, Geboers, Katrien, Petit, Benedicte, Langenaeken, Christine, Van Rijswijk, Ruud, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, Vandenborre, Katherine, Lobelle, Jean-Pierre, Lycke, Michelle, Milisen, Koen, Wildiers, Hans

“…This study aims to investigate health-related quality of life (HRQOL) at baseline and at follow-up in older patients with cancer and to determine prognostic…”
Get full text

The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors by Quinten, Chantal, Kenis, Cindy, Decoster, Lore, Debruyne, Philip R., De Groof, Inge, Focan, Christian, Cornelis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Luce, Syvlie, Debugne, Gwenaëlle, Van den Bulck, Heidi, Goeminne, Jean-Charles, Schrijvers, Dirk, Geboers, Katrien, Petit, Benedicte, Langenaeken, Christine, Van Rijswijk, Ruud, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, Vandenborre, Katherine, Lycke, Michelle, Flamaing, Johan, Milisen, Koen, Lobelle, Jean-Pierre, Wildiers, Hans

“…We aimed to determine the prognostic value of baseline Health-Related Quality Of Life (HRQOL) and geriatric assessment (GA) to predict three-month mortality in…”
Get full text

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? by Van Praet, Charles, Rottey, Sylvie, Van Hende, Fransien, Pelgrims, Gino, Demey, Wim, Van Aelst, Filip, Wynendaele, Wim, Gil, Thierry, Schatteman, Peter, Filleul, Bertrand, Schallier, Denis, Machiels, Jean-Pascal, Schrijvers, Dirk, Everaert, Els, D'Hondt, Lionel, Werbrouck, Patrick, Vermeij, Joanna, Mebis, Jeroen, Clausse, Marylene, Rasschaert, Marika, Van Erps, Joanna, Verheezen, Jolanda, Van Haverbeke, Jan, Goeminne, Jean-Charles, Lumen, Nicolaas

“…Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel…”
Get full text

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer by Mardjuadi, Feby Ingriani, Carrasco, Javier, Coche, Jean-Charles, Sempoux, Christine, Jouret-Mourin, Anne, Scalliet, Pierre, Goeminne, Jean-Charles, Daisne, Jean-François, Delaunoit, Thierry, Vuylsteke, Peter, Humblet, Yves, Meert, Nicolas, van den Eynde, Marc, Moxhon, Anne, Haustermans, Karin, Canon, Jean-Luc, Machiels, Jean-Pascal

“…Our goal was to optimize the radiosensitizing potential of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, when given concomitantly with…”
Get full text

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study by Neven, Patrick, Paridaens, Robert, Pelgrims, Gino, Martens, Marc, Bols, Alain, Goeminne, Jean Charles, Vindevoghel, Anita, Demol, Jan, Stragier, Barbara, De Greve, Jacques, Fontaine, Christel, Van Den Weyngaert, Danielle, Becquart, Dominique, Borms, Marleen, Cocquyt, Veronique, Van Den Broecke, Rudy, Selleslags, Jean, Awada, Ahmad, Dirix, Luc, Van Dam, Peter, Azerad, Marie Agnes, Vandenhoven, Guy, Christiaens, Marie Rose, Vergote, Ignace

“…Fulvestrant (Faslodex™) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with…”
Get full text

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial by Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

“…Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through…”
Get full text

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study by Pant, Shubham, Schuler, Martin, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Lugowska, Iwona, Carranza, Omar, Arnold, Dirk, Gutierrez, Martin, Winter, Helen, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann, Carranza, Omar, Coward, Jim, Joshua, Anthony, Karapetis, Christos, Hart, Christopher, Zhang, Alison, Prenen, Hans, Goeminne, Jean-Charles, Machiels, Jean-Pascal, Rottey, Sylvie, Corassa, Marcelo, Molin, Graziela Zibetti Dal, Tiscoski, Katsuki, Mak, Milena, Fu, Wei, Yao, Herui, Jiang, Haiping, Qin, Shukui, Chen, Baoshi, Yang, Yu, Loriot, Yohann, Le Tourneau, Christophe, Penel, Nicolas, Durando, Xavier, Emambux, Sheik, Folprecht, Gunnar, Arnold, Dirk, Schuler, Martin, Ahrens, Marit, Golf, Alexander, Haag, Georg Martin, Desuki, Alexander, Cazzaniga, Marina, Ciardiello, Fortunato, Koyama, Takafumi, Aogi, Kenjiro, Kuboki, Yasutoshi, Lee, Jungyun, Kim, Sung-Bae, Chang, Jong Hee, Kim, Yong-Man, Nam, Do-Hyun, Park, Jae-Sung, Lugowska, Iwona, Paz-Ares, Luis, Moreno, Victor, Calvo, Mariona, Falcon, Alejandro, Gonzalez, Antonio, Tabernero, Josep, Martinez Bueno, Alejandro, García-Corbacho, Javier, Chen, Jen-Shi, Hou, Ming-Feng, Chao, Yee, Rau, Kun-Ming, Chiu, Tai-Jan, Feng, Yin-Hsun, Hsu, Chih-Hung, Lai, Kuan-Ming, Yeh, Su-peng, Minchom, Anna, Welsh, Liam, Plummer, Ruth, Gutierrez, Martin, Arrowsmith, Edward, Pant, Shubham, Spigel, David Robert, Zandberg, Dan Paul, Doroshow, Deborah, Moezi, Mehdi, Paulson, Scott, Reardon, David, Ward, Patrick, Chaves, Jorge, Hussein, Atif, Manda, Sudhir, Richey, Stephen L, Tamura, David, Wilks, Sharon

“…FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective…”
Get full text

CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL by Reardon, David, Welsh, Liam, Shih, Kent, Shimizu, Toshio, Goeminne, Jean-Charles, Geoerger, Birgit, Baldini, Capucine, Massard, Christophe, Loriot, Yohann, Pant, Shubham, Sait, Sameer Farouk, Thomas, Shibu, Hammond, Constance, Najmi, Saltant, Triantos, Spyros, Crow, Lauren, Sweiti, Hussein, Witt, Olaf

Get full text